Business
Forte Biosciences raises USD 150m in public offering
Dallas-based Forte Biosciences, Inc. (Nasdaq: FBRX) announced the pricing of a USD 150 million public offering on April 8, 2026, with proceeds directed...
Life Biosciences secures USD 80 million Series D to advance ER-100 gene therapy
Boston-based Life Biosciences has closed a USD 80 million Series D financing round to advance ER-100, its lead gene therapy candidate for optic...
Astellas exercises USD 15m option on Dyno's AI-designed AAV capsid for skeletal muscle gene delivery
An AI-designed AAV capsid engineered for skeletal muscle gene delivery has moved from option to full license, with Astellas Pharma (TSE: 4503) exercising...
Cue Bio takes USD 7.5m milestone from Boehringer Ingelheim for bispecific B cell depleter
CUE-501, a preclinical bispecific fusion protein biologic described by Cue Biopharma (NASDAQ: CUE) as designed to selectively deplete pathogenic B cells via...
Incyclix Bio raises USD 5m Series B to advance CDK2 inhibitor in breast cancer study
Incyclix Bio, a cell cycle-focused oncology company headquartered in Research Triangle Park, North Carolina, has raised an additional USD 5 million in...
Sidewinder Therapeutics raises USD 137 million Series B for bispecific antibody-drug conjugates
San Diego-based Sidewinder Therapeutics has closed a USD 137 million Series B financing round to advance its pipeline of bispecific antibody-drug conjugates...
ReAlta Life Sciences closes USD 40m financing round for pegtarazimod HIE program
Norfolk, Virginia-based ReAlta Life Sciences Inc. has closed an oversubscribed USD 40 million financing round to advance pegtarazimod, its lead candidate...
Merck and Zhifei Biological restructure China vaccine distribution deal for Gardasil 9
Gardasil 9, RotaTeq, and Pneumovax 23 sit at the center of a restructured exclusive distribution and co-promotion agreement signed April 2, 2026, between...
Merck initiates tender offer for Terns Pharmaceuticals
Merck Expands Hematology Pipeline via USD 3.0 Billion Tender Offer for Terns Pharmaceuticals
Eli Lilly signs up new Tau aggregation inhibitor candidates from AC Immune with USD 12.5m upfront
Oral small molecule Tau aggregation inhibitors from AC Immune SA's (NASDAQ: ACIU) Morphomer platform are at the center of an amended license and...
Gilead Sciences expands ADC oncology pipeline with USD 5b acquisition of Tubulis
Gilead Sciences Expands ADC Oncology Pipeline with USD 5 Billion Acquisition of Tubulis
Takeda exits co-development of Denali's dementia drug
DNL593, a progranulin replacement biologic engineered with Denali Therapeutics' (NASDAQ: DNLI) TransportVehicle technology, will advance under sole Denali...
Apnimed preparing for sleep apnea drug approval with USD 150m debt, royalty deal
Cambridge, Massachusetts-based Apnimed, Inc. has secured up to USD 150 million in debt financing from HealthCare Royalty Partners to support commercial...
Esperion closes deal for Corstasis Therapeutics' Enbumyst and CVD franchise
Esperion Therapeutics Expands Cardiovascular Franchise via Acquisition of Corstasis Therapeutics and FDA-Approved Enbumyst
Pillar Biosciences, CellCarta partner on decentralized NGS tumor profiling for oncology trials
Pillar Biosciences' oncoReveal® NGS panel portfolio sits at the center of a multi-year global strategic partnership with CellCarta, a Montreal-based...
The AllSci Brief
Systematic R&D and deal news. Daily.